Ginkgo Bioworks Holdings, Inc. (DNA)
NYSE:DNA
Want to see DNA full AI Analyst Report?
DNA Stock Chart & Stats
$8.86
-$0.35(-3.13%)
At close: 4:00 PM EST
$8.86
-$0.35(-3.13%)
Day’s Range― - ―
52-Week Range$5.37 - $17.58
Previous CloseN/A
Volume618.97K
Average Volume (3M)1.44M
Market Cap
$522.60M
Enterprise Value$878.93M
Total Cash (Recent Filing)$373.46M
Total Debt (Recent Filing)$410.70M
Price to Earnings (P/E)―
Beta2.96
Next Earnings
Aug 06, 2026EPS Estimate
-1.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.37
Shares Outstanding53,361,140
10 Day Avg. Volume1,654,679
30 Day Avg. Volume1,442,292
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)2.71
P/FCF Ratio-2.58
Enterprise Value/Market Cap1.68
Enterprise Value/Revenue6.22
Enterprise Value/Gross Profit8.30
Enterprise Value/Ebitda-4.17
Forecast
1Y Price Target
$12.00Price Target Upside35.44% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-4.43
Revenue Forecast (FY)$159.47M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~81% gross margins indicate Ginkgo's platform and cell-engineering services capture significant value at the production layer. This margin profile gives structural room to cover fixed R&D and automation costs as revenue scales, supporting durable profitability if topline recovers.
Cash Position & No Bank DebtA $373M cash balance and absence of bank debt provide meaningful runway against the company's reaffirmed $125–$150M 2026 burn guidance. This financial cushion enables continued investment in Nebula and cloud initiatives without immediate refinancing risk, preserving strategic optionality.
Autonomous Lab Scale & Strategic ContractsExpansion from ~50 to 103–105 racks and broad device/protocol integration shows operational scale in automated labs. Durable platform scale and a $47M PNNL contract anchor commercialization pathways, increasing the odds that recurring service revenue can grow from platform adoption.
Bears Say
Steep Revenue DeclineSharp multi-period revenue contraction undermines leverage of high gross margins and strains the path to self-funded growth. Persistent top-line declines reduce ability to cover fixed automation and R&D costs, lengthening dependency on external funding until commercial traction returns.
Ongoing Cash Burn & Negative FCFSubstantial negative operating and free cash flow means the business still consumes capital despite cost reductions. Continued cash burn forces reliance on existing cash or new financing, which can constrain investment pacing and strategic flexibility if revenue recovery lags.
Unproven Revenue Translation From New ChannelsWhile channels (AWS, Benchling, cloud lab) expand addressable markets, they are nascent and unproven as reliable revenue drivers. If these channels take longer to convert customers or require more investment, the company may not realize expected durable revenue growth within its current cash runway.
Ginkgo Bioworks Holdings News
DNA FAQ
What was Ginkgo Bioworks Holdings, Inc.’s price range in the past 12 months?
Ginkgo Bioworks Holdings, Inc. lowest stock price was $5.37 and its highest was $17.58 in the past 12 months.
What is Ginkgo Bioworks Holdings, Inc.’s market cap?
Ginkgo Bioworks Holdings, Inc.’s market cap is $522.60M.
When is Ginkgo Bioworks Holdings, Inc.’s upcoming earnings report date?
Ginkgo Bioworks Holdings, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 55 days.
How were Ginkgo Bioworks Holdings, Inc.’s earnings last quarter?
Ginkgo Bioworks Holdings, Inc. released its earnings results on May 07, 2026. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.211 by -$0.179.
Is Ginkgo Bioworks Holdings, Inc. overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings, Inc.’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings, Inc. pay dividends?
Ginkgo Bioworks Holdings, Inc. does not currently pay dividends.
What is Ginkgo Bioworks Holdings, Inc.’s EPS estimate?
Ginkgo Bioworks Holdings, Inc.’s EPS estimate is -1.05.
How many shares outstanding does Ginkgo Bioworks Holdings, Inc. have?
Ginkgo Bioworks Holdings, Inc. has 53,361,140 shares outstanding.
What happened to Ginkgo Bioworks Holdings, Inc.’s price movement after its last earnings report?
Ginkgo Bioworks Holdings, Inc. reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.211. Following the earnings report the stock price went down -13.469%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings, Inc.?
Currently, no hedge funds are holding shares in DNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ginkgo Bioworks Holdings Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.00 (35.44% Upside)
$12.00 (35.44% Upside)
Blogger Sentiment
Neutral
DNA Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 201.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.20%
12-Months-Change
Fundamentals
Return on Equity
-57.31%
Trailing 12-Months
Asset Growth
-20.13%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., alongside its subsidiary entities, provides an advanced technological platform focused on the engineering of cells. This proprietary system is utilized to manipulate cellular functions, facilitating the biological creation of various products. These outputs span from innovative pharmaceutical treatments and vital food components to sustainable chemicals designed to replace those traditionally sourced from petroleum. The enterprise caters to a broad spectrum of industries, encompassing specialized chemical manufacturing, the agricultural sector, food production, consumer goods, and pharmaceuticals. Furthermore, Ginkgo Bioworks has forged a partnership with Selecta Biosciences, Inc., for the joint advancement of the ImmTOR technology platform. The company, founded in 2008, is headquartered in Boston, Massachusetts.
DNA Company Deck
DNA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: meaningful operational and strategic progress in autonomous labs (Nebula), AI-driven experiments, partnerships and a strong cash position, alongside significant near-term financial challenges including a sharp revenue decline, ongoing losses, negative adjusted EBITDA and cash costs from excess leases and one-time payments. Execution and commercialization of Nebula, cloud lab and channel partnerships will determine whether the recent technical and commercial wins translate into durable revenue growth.View all DNA earnings summariesDNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
DNA Stock 12 Month Forecast
Average Price Target
$12.00
▲(35.44% Upside)
Technical Analysis
Niagen Bioscience
―
Monopar Therapeutics Inc
―
Lyell Immunopharma
―
Jade Biosciences
―
AbSci
―
Ownership Overview
3.13% Insiders
15.84% Mutual Funds
25.72% Other Institutional Investors
41.36% Public Companies and Individual Investors